AbbVie Inc. or Dr. Reddy's Laboratories Limited: Who Invests More in Innovation?

Pharma Giants' R&D Race: AbbVie vs. Dr. Reddy's

__timestampAbbVie Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014329700000012402000000
Thursday, January 1, 2015428500000017449000000
Friday, January 1, 2016436600000017834000000
Sunday, January 1, 2017498200000019551000000
Monday, January 1, 20181032900000018265000000
Tuesday, January 1, 2019640700000015607000000
Wednesday, January 1, 2020655700000015410000000
Friday, January 1, 2021708400000016541000000
Saturday, January 1, 2022651000000017482000000
Sunday, January 1, 2023845300000019381000000
Monday, January 1, 20241279100000022873000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, innovation is the lifeblood that drives progress and success. Over the past decade, AbbVie Inc. and Dr. Reddy's Laboratories Limited have been at the forefront of this innovation race. From 2014 to 2023, Dr. Reddy's Laboratories consistently outpaced AbbVie in research and development (R&D) spending, investing nearly 50% more on average each year. In 2018, AbbVie made a significant leap, doubling its R&D expenses compared to 2014, yet it still trailed behind Dr. Reddy's. By 2023, Dr. Reddy's had increased its R&D investment by approximately 56% since 2014, reaching a peak in 2024. This trend underscores the company's commitment to pioneering new treatments and technologies. As the data reveals, while both companies are dedicated to innovation, Dr. Reddy's Laboratories has maintained a more aggressive investment strategy in recent years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025